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CLINICAL APPROACH TO THE DIAGNOSIS OF DISEASES AND DISORDERS
IN PETS AND DOMESTIC ANIMALS SOMETIMES MISTAKEN FOR ANTICOAGULANT TOXICOSIS
BENNY J. WOODY, College of Veterinary Medicine Mississippi State University, Drawer V, Mississippi State, Mississippi 39762
ABSTRACT: To differentiate the causes of bleeding disorders requires a basic understanding of the hemostatic process and
the proper interpretation of history, physical examination, and laboratory tests. A brief overview of the hemostatic process is
presented. Tables and flow charts are provided to assist in developing a sound clinical approach to the bleeding patient through
the proper assessment of history, physical examination findings, and laboratory tests. Categories of inherited and acquired
bleeding disorders are briefly presented.
Proc. 15th Vertebrate Pest Conf. (J. E. Borrecco & R. E. Marsh,
Editors) Published at University of Calif., Davis. 1992

INTRODUCTION
Patients with inherited and acquired bleeding disorders
are commonly encountered in clinical veterinary medicine.
Over the past 40 years, a variety of disease processes that
result in bleeding disorders have been described in the veterinary literature. Animals have been found to have most of
the inherited and acquired bleeding disorders found in humans (Dodds 1988). Causes of these bleeding disorders can
be categorized into abnormalities involving the blood vessel,
the platelet, coagulation factors or the fibrinolytic process
(Table 1). These abnormalities may occur independently or
concurrently and clinical signs associated with them are often very similar. This compartmentalized approach aids in
understanding the major processes of hemostasis; however,
one must realize that interrelationships exist between all
components of the hemostatic process. Clinical and laboratory assessment of the bleeding patient requires a basic understanding of the hemostatic process.
OVERVIEW OF NORMAL HEMOSTASIS
Effective hemostasis is accomplished through a sequence of integrated functions involving the blood vessels,
platelets, plasma coagulation factors and the fibrinolytic system (Feldman et al. 1986). When the vessel wall integrity of
a small artery or vein is broken, localized vasoconstriction
normally occurs. This slows blood flow and facilitates the
accumulation of platelets. Also, endothelium damage in a
vessel exposes surfaces that promote platelet adherence,
platelet aggregation and platelet release reactions. The substances released from platelets further stimulate platelet aggregation, help to maintain vasoconstriction, and contribute
to the coagulation process. The initial platelet plug which is
formed at the site of injury is stabilized and eventually replaced with fibrin through the complex system of blood coagulation.
Blood coagulation occurs through a series of step-bystep biochemical reactions, in which an inactive coagulation
factor is converted to an active coagulation factor. This active factor, in turn, converts another inactive factor to its
active form. This cycle continues until fibrinogen is converted to fibrin and the fibrin is cross-linked to form a stable
fibrin clot (Figure 1). The coagulation system can be activated and proceed by either of two pathways, the intrinsic
system or the extrinsic system. In vivo, activity through both
systems is important; however, the concept of two separate

pathways helps in the evaluation of laboratory tests and in the
categorization of coagulopathies.
The extrinsic system is initiated when tissue extracts (i.e.,
tissue thromboplastin) are released from damaged endothelial
cells and complex with Factor VII. The intrinsic system is
initiated when substances such as collagen, platelets or endotoxin activate Factor XII. Both systems share a final common
pathway that leads to the formation of a stable fibrin clot. This
common pathway begins with the activation of Factor X. Activated Factor X in the presence of calcium and Factor V converts prothrombin (Factor II) to thrombin which in turn
converts fibrinogen (Factor I) to fibrin. Fibrin is then crosslinked to form a stable fibrin clot. Eventually, the fibrin clot is
removed through the process of fibrinolysis.
CLINICAL ASSESSMENT
Medical History and Physical Examination
The first step in the clinical assessment of the bleeding
patient is the development of a complete medical history. The
history should contain all of the following: chief complaint,
signalment (i.e., age, breed, sex), details of present illness, past
medical or surgical problems, health maintenance (i.e., vaccinations, routine diagnostic testing, treatments), previous and

Figure 1. Schematic depicting the intrinsic and extrinsic coagulation pathways.
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Table 1. Categorization of hemostatic disorders identified in animals.

(Modified from Lewis and Dhein, 1990).
present drug history, diet, environment, family history, and a
general systems review (e.g., coughing, sneezing, vomiting,
diarrhea, discharges, lameness, appetite, water consumption,
urination, weight gain or loss, etc.)
Particular attention should be given to the signalment,
family history, drug history, and environment (Table 2). The
signalment and family history can provide valuable information to support whether the bleeding disorder is inherited or
acquired. Inherited disorders tend to become evident early in
life, usually during the first 6 to 12 months (Troy 1984). A
history of excessive bleeding associated with minor trauma,
loss of deciduous teeth, or elective surgical procedures (e.g.,
ear cropping, tail docking, onchyectomy, ovariohysterectomy,
castration, etc.) is supportive of an inherited hemostatic defect. However, some mild forms of inherited hemostatic defects may not be evident until the animal is an adult (i.e., von
Willebrand's disease). Information regarding bleeding disorders in close relatives may provide information to support an
inherited disorder. Since some inherited bleeding disorders
(i.e., hemophilia A and hemophilia B) are transmitted as recessive sex-linked traits, these disorders are seen primarily in
the male with the female being an asymptomatic carrier
(Johnston 1988). Inherited bleeding disorders are more com-

mon in purebred animals and some inherited bleeding disorders occur with a high frequency within a particular breed, for
example von Willebrand's disease in doberman pinschers.
A detailed history of recent or current drug administration including vaccinations must be obtained. Drugs such as
aspirin and other non-steroidal anti-inflammatory drugs, and
some antibiotics interfere with normal platelet function.
Modified-live virus vaccines can cause a decrease in platelet
numbers for up to 10 days following vaccination (Johnston
1989). Although alone, most of these drugs do not cause
clinical bleeding in a normal animal; however, when administered to an animal with a pre-existing hemostatic defect
they may lead to a severe bleeding episode. Review of past
medical problems and treatments is helpful when attempting
to determine underlying or concurrent conditions which could
contribute to the hemostatic compromise. Underlying neoplastic diseases, organ failure, infectious agents, and inflammatory processes are likely reasons for hemostatic disorders
to occur in the adult animal (Troy 1984). Environmental history is important when attempting to ascertain the likelihood
of exposure to toxic drugs or chemicals such as anticoagulant
rodenticides.
A complete physical examination must be performed to
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Table 3. Physical findings and their relationship to the
hemostatic process.

Table 2. Historical questions which are essential to ask in the
work-up of a bleeding patient.

time (ACT), one-stage prothrombin time (OSPT), thrombin
clotting time (TT), proteins involved in vitamin K absence or
antagonism (PIVKA), fibrinogen, and fibrin degradation
products (FDPs). Each of these screening tests have been
described in detail in previous publications (Davey 1979,
Feldman et al. 1986, Johnston 1989, Lewis and Dhein 1990).
The clinical applications of the screening tests are depicted in
Figures 2 and 3.
Results of the clinical evaluation and coagulation screening tests may dictate that more specific and specialized testing be performed to obtain a definitive diagnosis. Some of the
specialized tests include specific factor assays for inherited
factor deficiencies, platelet aggregation for platelet function
defects, bone marrow evaluation for qualitative platelet disorders, Factor VIII-related antigen for von Willebrand's disease, toxicological assays for anticoagulant rodenticides, and
anti-thrombin III levels for the management of DIC.

determine the nature of the hemorrhage. The nature of the
bleeding may be particularly useful when attempting to determine if the bleeding episode is primarily due to vascular,
platelet, or coagulation factor abnormalities (Table 3). In an
attempt to identify additional diseases or conditions which
may be causing or contributing to the hemostatic compromise, physical findings in addition to the bleeding (e.g., fever,
lymphadenomegaly, splenomegaly, hepatomegaly, mental
status, heart and lung sounds, abdominal distension, joint distension, lameness, icterus, mucous membrane color, etc.)
must be noted. These additional physical findings may provide clues as to the cause of the hemorrhage.
Laboratory Evaluation
Although a specific hemostatic abnormality can be suspected from a complete history and physical examination,
laboratory testing is usually essential in the determination of a
definitive diagnosis. A minimum data base for the patient
(e.g., complete blood count, biochemical profile, urinalysis,
fecal examination, etc.) should be obtained in an attempt to
identify additional diseases or conditions which may be causing or contributing to the hemostatic compromise or which
may affect treatment. Laboratory tests for evaluating the hemostatic process can be divided into two categories: screening tests and specialized tests. The screening laboratory tests
should be chosen to evaluate all components of the hemostatic process. Once this is accomplished, more specific testing may be required to obtain a definitive diagnosis.
The most commonly performed screening tests (Table 4)
include the platelet count, mucosal bleeding time, activated
partial thromboplastin time (APTT), activated coagulation

201

CLINICAL DISORDERS
Vascular Disorders
Defects in blood vessels may be inherited or acquired.
Ehlers-Danlos syndrome is the best described inherited vascular disease in which abnormal collagen weakens vessel
support so that bleeding occurs. Acquired vascular disorder
may be due to vasculitis. Common causes of vasculitis include immune-mediated mechanisms, viral infections, and
rickettsial infections (Troy 1984). Prolonged mucosal bleeding time with the exclusion of thrombocytopenia, platelet
dysfunction and normal coagulation tests are the most accessible methods for the diagnosis of vascular abnormalities.
Thrombocytopenia
Thrombocytopenia may be inherited or acquired; however, acquired causes of thrombocytopenia are much more
common in veterinary medicine. Thrombocytopenia is due to
decreased production, increased usage, increased destruction,
or sequestration of the platelets (Table 1). Spontaneous hemorrhage rarely occurs until the platelet count is less than
50,000 per microliter (normal platelet count, greater than
200,000 per microliter). Hemorrhage occurring in patients

Table 4. Screening laboratory tests used to evaluate the hemostatic process.

with platelet counts greater than 50,000 per microliter is indicative of concurrent vessel abnormalities, platelet function
abnormalities, or coagulopathy.
Bone marrow evaluation is indicated in thrombocytopenic animals. Increased numbers of megakaryocytes in
the bone marrow is suggestive of diseases causing either increased usage or destruction of the circulating platelet.
Whereas, decreased numbers of megakaryocytes in the
bone marrow is suggestive of disease processes leading to
decreased production.

Figure 2. An algorithm for the clinical approach to the patient
with abnormal hemostasis and a decreased platelet count (modified from Troy, 1984).

Thrombocytopathia
Thrombocytopathia or qualitative platelet defects may
be inherited or acquired. These defects in platelet function
may cause abnormalities in platelet adhesion, aggregation,
and release reactions.
Von Willebrand's disease is the most frequently reported
inherited thrombocytopathia characterized by decreased
platelet adhesiveness. Von Willebrand's disease is inherited
as an autosomal recessive or as an autosomal incomplete
dominant trait (Troy 1984). In most cases of von Willebrand's
disease, spontaneous bleeding is not clinically evident.
Bleeding disorders are recognized when an animal undergoes
surgery or sustains trauma. However, coexisting disease processes such as hypothyroidism, uremia, liver disease, drug
administration, or infections may cause severe bleeding. Von
Willebrand's disease has been diagnosed in a large number of
dog breeds and occasionally in cats, pigs and horses. A high
incidence of von Willebrand's disease has been reported in
the following breeds of dogs: doberman pinscher, Shetland
sheepdog, golden retriever, German shepherd, Scottish terrier, miniature schnauzer, Welsh Pembroke corgi, Manchester
terrier and basset hound. Von Willebrand's disease should be
suspected in patients with prolonged mucosal bleeding time
with normal platelet counts and coagulation tests. Specific
diagnosis is based on Factor VIII-related antigen assay.
Defects in platelet aggregation is seen as an inherited
disorder in the otterhound (thrombasthenia) and in the fox
hound, basset hound and cats (thrombopathia). Defects of
acquired platelet aggregation is most often secondary to drug
administration (especially non-steroidal anti-inflammatory
drugs) or due to gammopathies.

Figure 3. An algorithm for the clinical approach to the patient
with abnormal heomstasis and a normal platelet count (modified from Troy, 1984).
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Table 5. Hereditary coagulopathies and animal species
reported to be affected.

Liver Disease
Bleeding disorders associated with liver disease are often multifactorial. All coagulation factors except for Factor
VIII are produced by the liver. Patients with liver disease are
often thrombocytopenic. This is partially due to platelet sequestration associated with portal hypertension and splenic
enlargement. Patients with liver disease may also develop
DIC leading to thrombocytopenia, coagulation factor deficiencies, and increased FDPs. The liver normally aids in the
removal of FDPs from circulation. In liver disease, FDPs
accumulate and lead to further defects in coagulation. Patients with chronic liver disease may also synthesize an abnormal fibrinogen which interferes with the formation of a
stable fibrin clot (Feldman 1981).

Hereditary Coagulopathies
Hereditary coagulopathies are less common than acquired coagulopathies. They are generally due to a single
factor deficiency. Regardless of the type of coagulopathy,
clinical signs are similar. Table 5 provides a listing of reported hereditary coagulopathies and the species affected
(Feldman 1986).
Acquired Coagulopathies
Clinically, acquired coagulopathies can generally be
viewed as either vitamin K antagonism/deficiency, liver disease, or disseminated intravascular coagulopathy (DIC).
Vitamin K is required for carboxylation of glutamic acid
residues in Factors II, VII, IX and X. When these coagulation
factors are produced in the absence of vitamin K they are
inactive. Since Factor VII (extrinsic system) has the shortest
half-life (4 to 6 hours) of the vitamin K-dependent coagulation factors, prolongation of the OSPT is recognized prior to
prolongation of the APTT or ACT (Feldman 1981). The
PIVKA test detects non-functional precursors of the vitamin
K-dependent coagulation factors. The PIVKA test will become positive 12 to 24 hours prior to prolongation of the
OSPT (Lewis and Dhein 1990).
Animals require a continuous supply of vitamin K since
storage of vitamin K is limited to only a few days. Vitamin K
is found in vegetable oils and leafy plants and it is synthesized by gastrointestinal bacteria. Vitamin K is fat soluble
and bile acids are required to emulsify fats to facilitate its
absorption from the gastrointestinal tract. Vitamin K deficiency may develop due to gastrointestinal disorders (i.e., fat
malabsorption, complete bile duct obstruction, pancreatic
exocrine insufficiency and gastrointestinal tract sterilization
with antibiotics) (Feldman 1981, Feldman 1986). Even
though vitamin K deficiency has been reported in animals,
vitamin K antagonism secondary to anticoagulant rodenticides ingestion is much more common.

Disseminated Intravascular Coagulopathy
Disseminated intravascular coagulopathy commonly occurs secondary to a wide variety of clinical conditions. Any
disease which produces vascular stasis or breakdown of vascular endothelium favors the induction of DIC. Activation of
the coagulation system leads to uncontrolled microvascular
thrombosis. Bleeding tendencies develop as coagulation factors and platelets are consumed and these bleeding tendencies
are potentiated as FDPs accumulate due to uncontrolled fibrinolysis. Diagnosis of DIC is supported by thrombocytopenia, prolongation of APTT, ACT and OSPT, and
elevations of FDPs. Since DIC is always secondary to another disease process, treatment, where possible, must be directed at the underlying cause.

203

LITERATURE CITED
DAVEY, F.R. 1979. Blood coagulation and its disorders. In:
Clinical diagnosis and management by laboratory methods, 16th ed. (J.B. Henry, ed), W.B. Saunders Co., Philadelphia, PA, pp. 1131-1170.
DODDS, W.J. 1988. Introduction to hemostasis. Veterinary
Clinics of North America [Small Animal Practice] 18:12.
FELDMAN, B.F. 1981. Coagulopathies in small animals.
Journal of the American Veterinary Medical Association
179: 559-563.
FELDMAN, B.F., E.J. CARROLL, and N.C. JAIN. 1986.
Coagulation and its disorders. In: Schalm's veterinary
hematology, 4th ed. (N.C. Jain, ed.), Lea & Febiger,
Philadelphia, PA, pp. 388-430.
JOHNSTON, I.B. 1988. Spontaneous or prolonged bleeding.
In: Clinical signs and diagnosis in small animal practice
(R.B. Ford, ed.), Churchill Livingston, Inc., New York,
NY, pp. 103-116.
JOHNSTON, I.B. 1989. Diagnostic approach to the bleeding
patient. In: Current veterinary therapy X (R.W. Kirk,
ed.), W.B. Saunders Co., Philadelphia, PA, pp. 436442.
LEWIS, D.C. and C.R. DHEIN. 1990. Spontaneous or prolonged bleeding. Kal Kan Forum 9(1): 7-14.
TROY, G.C. 1984. Clinical approach to hemostatic disorders. Veterinary Medicine 79:917-930.

